Glenmark, Sun Pharma, and Zydus are recalling various products in the US due to manufacturing issues and CGMP deviations, according to the ...

Gabapentin, approved for seizures and postherpetic neuralgia, has become widely used off-label for ailments like fibromyalgia, neuropathy, ...

Zydus Lifesciences announced that it has obtained approval from the USFDA to sell a generic medication for the treatment of postherpetic ne...

These tablets are bioequivalent to the reference listed drug product, Neurontin Tablets, 600 mg and 800 mg, of Viatris Specialty LLC.

Glenmark Pharmaceuticals Ltd has received final approval from the United States Food and Drug Administration (USFDA) for Tadalafil tablets ...

Buy Hikal at a price target of Rs 218.

The company's tablets are generic version of Pfizer Inc's Neurontin tablets in the same strengths, Lupin said.

The company has initiated necessary measures to address the concerns raised by the US-FDA and is making all efforts to fully meet the compl...

In a filing to BSE, the drug marker said that the USFDA has exempted the company from making ten drugs.

The drug is manufactured by Aurobindo Pharma at its Mahabub Nagar facility in Andhra Pradesh.

US-based unit of drug firm Aurobindo Pharma is voluntarily recalling a lot Gabapentin capsules, an anti-epilepsy drug, in the American mark...

Glenmark Generics is recalling multiple lots of three of its drugs from the US market due to "odd smell", according to US FDA.

Former chief justice of Delhi High Court Rajinder Sachar has demanded that Indian authorities take steps to stop their use in the country.

The Generic drugmaker pleaded guilty to felony charges related to drug safety and will pay $500 mn in civil and criminal fines.

Ranbaxy pleaded guilty to felony charges related to drug safety & will pay $500 mn in fines under settlement agreement with US Department o...

The company recalled Gabapentin tablets after discovering impurities outside the approved specification limit. Day in pics | Master your tr...

Mumbai-based drug firm Sun Pharma is planning to hive-off its research operations into a separate entity.